Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2

Wonkyung Oh, Eun Woo Lee, Hoon Sung Young, Mi Ran Yang, Jaewang Ghim, Han Woong Lee, Jaewhan Song

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The biological mechanisms for maintaining the basal level of p53 in normal cells require nuclear exclusion and cytoplasmic degradation. Here, we showed that Jab1 facilitates p53 nuclear exclusion and its subsequent degradation in coordination with Hdm2. p53 was excluded from the nucleus in the presence of Jab1; this exclusion was prevented by leptomycin B treatment. Nuclear export of p53 was accompanied by a decrease in the levels of p53, as well as of its target proteins, which include p21 and Bax. Domain analyses of Jab1 showed that the N-terminal domain, 1-110, was capable of inducing cytoplasmic translocation of p53. Furthermore, 110-191 was required to facilitate the degradation of p53. Neither of these mutants incorporated into the CSN complex, indicating that Jab1 could affect the levels of p53 independent of intact CSN complex. Conversely, Jab1 was incapable of translocating and degrading two p53 mutants, W23S and 6KR, neither of which could be modified by Hdm2. Moreover, Jab1 did not affect the cellular localization or protein levels of p53 in p53 and Hdm2 double-null mouse embryo fibroblasts. We further observed that the ablation of endogenous Jab1 by small interfering RNA prevented Hdm2-mediated p53 nuclear exclusion. Under stressed conditions, which could sequester Hdm2 in its inactive state, Jab1 did not affect p53. Our studies implicate that Jab1 is required to remove post-translationally modified p53 and provide a novel target for p53-related cancer therapies.

Original languageEnglish
Pages (from-to)17457-17465
Number of pages9
JournalJournal of Biological Chemistry
Volume281
Issue number25
DOIs
Publication statusPublished - 2006 Jun 23

Fingerprint

Degradation
Cell Nucleus Active Transport
Second Primary Neoplasms
Small Interfering RNA
Proteins
Embryonic Structures
Fibroblasts
Ablation
leptomycin B

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Oh, Wonkyung ; Lee, Eun Woo ; Young, Hoon Sung ; Yang, Mi Ran ; Ghim, Jaewang ; Lee, Han Woong ; Song, Jaewhan. / Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. In: Journal of Biological Chemistry. 2006 ; Vol. 281, No. 25. pp. 17457-17465.
@article{771a827882b34b6db802e54bc1a4928e,
title = "Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2",
abstract = "The biological mechanisms for maintaining the basal level of p53 in normal cells require nuclear exclusion and cytoplasmic degradation. Here, we showed that Jab1 facilitates p53 nuclear exclusion and its subsequent degradation in coordination with Hdm2. p53 was excluded from the nucleus in the presence of Jab1; this exclusion was prevented by leptomycin B treatment. Nuclear export of p53 was accompanied by a decrease in the levels of p53, as well as of its target proteins, which include p21 and Bax. Domain analyses of Jab1 showed that the N-terminal domain, 1-110, was capable of inducing cytoplasmic translocation of p53. Furthermore, 110-191 was required to facilitate the degradation of p53. Neither of these mutants incorporated into the CSN complex, indicating that Jab1 could affect the levels of p53 independent of intact CSN complex. Conversely, Jab1 was incapable of translocating and degrading two p53 mutants, W23S and 6KR, neither of which could be modified by Hdm2. Moreover, Jab1 did not affect the cellular localization or protein levels of p53 in p53 and Hdm2 double-null mouse embryo fibroblasts. We further observed that the ablation of endogenous Jab1 by small interfering RNA prevented Hdm2-mediated p53 nuclear exclusion. Under stressed conditions, which could sequester Hdm2 in its inactive state, Jab1 did not affect p53. Our studies implicate that Jab1 is required to remove post-translationally modified p53 and provide a novel target for p53-related cancer therapies.",
author = "Wonkyung Oh and Lee, {Eun Woo} and Young, {Hoon Sung} and Yang, {Mi Ran} and Jaewang Ghim and Lee, {Han Woong} and Jaewhan Song",
year = "2006",
month = "6",
day = "23",
doi = "10.1074/jbc.M601857200",
language = "English",
volume = "281",
pages = "17457--17465",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "25",

}

Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. / Oh, Wonkyung; Lee, Eun Woo; Young, Hoon Sung; Yang, Mi Ran; Ghim, Jaewang; Lee, Han Woong; Song, Jaewhan.

In: Journal of Biological Chemistry, Vol. 281, No. 25, 23.06.2006, p. 17457-17465.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2

AU - Oh, Wonkyung

AU - Lee, Eun Woo

AU - Young, Hoon Sung

AU - Yang, Mi Ran

AU - Ghim, Jaewang

AU - Lee, Han Woong

AU - Song, Jaewhan

PY - 2006/6/23

Y1 - 2006/6/23

N2 - The biological mechanisms for maintaining the basal level of p53 in normal cells require nuclear exclusion and cytoplasmic degradation. Here, we showed that Jab1 facilitates p53 nuclear exclusion and its subsequent degradation in coordination with Hdm2. p53 was excluded from the nucleus in the presence of Jab1; this exclusion was prevented by leptomycin B treatment. Nuclear export of p53 was accompanied by a decrease in the levels of p53, as well as of its target proteins, which include p21 and Bax. Domain analyses of Jab1 showed that the N-terminal domain, 1-110, was capable of inducing cytoplasmic translocation of p53. Furthermore, 110-191 was required to facilitate the degradation of p53. Neither of these mutants incorporated into the CSN complex, indicating that Jab1 could affect the levels of p53 independent of intact CSN complex. Conversely, Jab1 was incapable of translocating and degrading two p53 mutants, W23S and 6KR, neither of which could be modified by Hdm2. Moreover, Jab1 did not affect the cellular localization or protein levels of p53 in p53 and Hdm2 double-null mouse embryo fibroblasts. We further observed that the ablation of endogenous Jab1 by small interfering RNA prevented Hdm2-mediated p53 nuclear exclusion. Under stressed conditions, which could sequester Hdm2 in its inactive state, Jab1 did not affect p53. Our studies implicate that Jab1 is required to remove post-translationally modified p53 and provide a novel target for p53-related cancer therapies.

AB - The biological mechanisms for maintaining the basal level of p53 in normal cells require nuclear exclusion and cytoplasmic degradation. Here, we showed that Jab1 facilitates p53 nuclear exclusion and its subsequent degradation in coordination with Hdm2. p53 was excluded from the nucleus in the presence of Jab1; this exclusion was prevented by leptomycin B treatment. Nuclear export of p53 was accompanied by a decrease in the levels of p53, as well as of its target proteins, which include p21 and Bax. Domain analyses of Jab1 showed that the N-terminal domain, 1-110, was capable of inducing cytoplasmic translocation of p53. Furthermore, 110-191 was required to facilitate the degradation of p53. Neither of these mutants incorporated into the CSN complex, indicating that Jab1 could affect the levels of p53 independent of intact CSN complex. Conversely, Jab1 was incapable of translocating and degrading two p53 mutants, W23S and 6KR, neither of which could be modified by Hdm2. Moreover, Jab1 did not affect the cellular localization or protein levels of p53 in p53 and Hdm2 double-null mouse embryo fibroblasts. We further observed that the ablation of endogenous Jab1 by small interfering RNA prevented Hdm2-mediated p53 nuclear exclusion. Under stressed conditions, which could sequester Hdm2 in its inactive state, Jab1 did not affect p53. Our studies implicate that Jab1 is required to remove post-translationally modified p53 and provide a novel target for p53-related cancer therapies.

UR - http://www.scopus.com/inward/record.url?scp=33745218066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745218066&partnerID=8YFLogxK

U2 - 10.1074/jbc.M601857200

DO - 10.1074/jbc.M601857200

M3 - Article

C2 - 16624822

AN - SCOPUS:33745218066

VL - 281

SP - 17457

EP - 17465

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 25

ER -